These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21244102

  • 1. Cost effectiveness of treatments for wet age-related macular degeneration.
    Mitchell P, Annemans L, White R, Gallagher M, Thomas S.
    Pharmacoeconomics; 2011 Feb; 29(2):107-31. PubMed ID: 21244102
    [Abstract] [Full Text] [Related]

  • 2. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?
    Virgili G, Novielli N, Menchini F, Murro V, Giacomelli G.
    Curr Drug Targets; 2011 Feb; 12(2):212-20. PubMed ID: 20887240
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation.
    Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, Hopkins R, McGahan L, Sharma S, Pan I, Blair J, Vollman D, Morrison A.
    Can J Ophthalmol; 2010 Jun; 45(3):223-30. PubMed ID: 20628420
    [Abstract] [Full Text] [Related]

  • 6. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J, Říhová B, Rencová E, Rozsíval P, Dubská Z, Chrapek O, Kolář P, Kandrnal V, Demlová R, Pitrová Š, Řehák J.
    Ophthalmologica; 2013 Jun; 230(1):34-42. PubMed ID: 23751929
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [Abstract] [Full Text] [Related]

  • 8. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
    Yanagi Y, Aihara Y, Fukuda T, Hashimoto H.
    Nippon Ganka Gakkai Zasshi; 2011 Sep; 115(9):825-31. PubMed ID: 22073599
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.
    Yanagi Y, Fukuda A, Barzey V, Adachi K.
    J Med Econ; 2017 Feb; 20(2):204-212. PubMed ID: 27701921
    [Abstract] [Full Text] [Related]

  • 12. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 13. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.
    Wickens J, Blinder KJ.
    Drug Saf; 2006 Feb; 29(3):189-99. PubMed ID: 16524319
    [Abstract] [Full Text] [Related]

  • 14. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [Abstract] [Full Text] [Related]

  • 15. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P, Kankaanpää E.
    Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.